生物制剂在过敏反应治疗中的应用。
Biologic Agents for the Treatment of Anaphylaxis.
机构信息
Hospital Sírio-Libanês; University Hospital of Montpellier, Montpellier, France; Sorbonne Université, INSERM UMR-S 1136, IPLESP, Equipe EPAR, Paris 75013, France; WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.
Department of Medicine, The Ohio State University, 410 West 10th Avenue, Columbus, OH 43210, USA.
出版信息
Immunol Allergy Clin North Am. 2020 Nov;40(4):625-633. doi: 10.1016/j.iac.2020.06.006. Epub 2020 Sep 12.
Several biologic therapies and new devices are emerging as potential preventive treatment of anaphylaxis. However, adrenaline (epinephrine) is still the first-line treatment of any type of anaphylaxis. Biologic drugs, such as omalizumab, although not US Food and Drug Administration approved for anaphylaxis, have been used as therapeutic adjuvants in the preventive treatment of anaphylaxis, but cost-effectiveness should be considered individually.
几种生物疗法和新设备作为潜在的过敏反应预防治疗手段正在出现。然而，肾上腺素（epinephrine）仍然是任何类型过敏反应的一线治疗药物。虽然奥马珠单抗（omalizumab）等生物药物尚未获得美国食品和药物管理局（US Food and Drug Administration）批准用于过敏反应，但已被用作过敏反应预防治疗的辅助治疗药物，但应考虑个体的成本效益。
Zotero 插件